Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?

Treatment of multiple myeloma (MM) has significantly improved, although the disease remains incurable. Prospective clinical trials evaluating the impact on outcome of new drugs such as proteasome inhibitors or immunomodulating agents are limited since they are not able to reflect the clinical routin...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2016-03, Vol.36 (3), p.1059-1065
Main Authors: Mian, Michael, Tinelli, Martina, DE March, Elena, Turri, Gloria, Meneghini, Vittorio, Pescosta, Norbert, Berno, Tamara, Marabese, Alessandra, Mondello, Patrizia, Patriarca, Francesca, Pizzolo, Giovanni, Semenzato, Gianpietro, Cortelazzo, Sergio, Zambello, Renato
Format: Article
Language:English
Subjects:
Bortezomib - administration & dosage
Bortezomib - therapeutic use
Humans
Leukemia, Plasma Cell - drug therapy
Leukemia, Plasma Cell - surgery
Multiple Myeloma - drug therapy
Multiple Myeloma - surgery
Prognosis
Retrospective Studies
Salmonidae
Stem Cell Transplantation
Survival Analysis
Thalidomide - administration & dosage
Thalidomide - analogs & derivatives
Thalidomide - therapeutic use
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment of multiple myeloma (MM) has significantly improved, although the disease remains incurable. Prospective clinical trials evaluating the impact on outcome of new drugs such as proteasome inhibitors or immunomodulating agents are limited since they are not able to reflect the clinical routine and available retrospective data are not detailed enough to directly evaluate the value of new drugs. To address these information gaps, we performed a retrospective real-life analysis. We retrospectively assessed 949 patients treated for multiple myeloma or plasma cell leukemia at three Italian cancer centers in the years 1979-2014. Clinical features at the time of diagnosis were consistent with what was observed in clinical routine. A total of 39% of patients underwent high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). The median overall survival (OS) of the whole group was 5.4 years and ranged from 3.4 years for patients who did not receive at least one of the new drugs compared to 5.9 years in the other patients (p
ISSN:0250-7005
1791-7530